- 大部份公司都有淡旺季, 所以通常是看年增率
- 如果是成長期(在炒新的成長動能)的公司或景氣從谷底翻揚, 就可以觀察月增率
- 漲很多的股票要留意營收年增率或月增率大幅減少, 又或者是合約負債已經開始減少
- 留意短期平均營收向上或向下穿越長期平均營收
- 觀察累計營收年增率的累計增加或虧損收斂
| 年/月 | 營收 | 月增率(%) | 去年同期年增率(%) | 累計營收 | 累計營收年增率(%) | 近三月累計營收 | 存貨銷售比 | 自結稅前EPS | 自結稅前累計EPS | 備註(年增率變動50%需說明原因) |
|---|---|---|---|---|---|---|---|---|---|---|
| 2024/11 | 2.48 | -6.71 | 20.02 | 26.45 | 28.75 | 7.7 | N/A | - | ||
| 2024/10 | 2.65 | 3.42 | 30.44 | 23.97 | 29.72 | 7.7 | N/A | - | ||
| 2024/9 | 2.57 | 3.42 | 26.61 | 21.32 | 29.63 | 7.37 | 0.45 | - | ||
| 2024/8 | 2.48 | 6.75 | 28.97 | 18.75 | 30.06 | 7.14 | 0.46 | - | ||
| 2024/7 | 2.32 | -0.26 | 19.22 | 16.27 | 30.22 | 6.99 | 0.47 | - | ||
| 2024/6 | 2.33 | -0.29 | 35.44 | 13.94 | 32.26 | 6.94 | 0.36 | - | ||
| 2024/5 | 2.34 | 2.99 | 32.98 | 11.61 | 31.64 | 7.06 | 0.36 | - | ||
| 2024/4 | 2.27 | -7.29 | 39.59 | 9.27 | 31.3 | 6.86 | 0.37 | - | ||
| 2024/3 | 2.45 | 14.18 | 37.52 | 7.0 | 28.82 | 7.0 | 0.31 | - | ||
| 2024/2 | 2.14 | -11.04 | 24.63 | 4.56 | 24.59 | 6.64 | 0.33 | - | ||
| 2024/1 | 2.41 | 15.37 | 24.56 | 2.41 | 24.56 | 6.56 | 0.33 | - | ||
| 2023/12 | 2.09 | 1.26 | 27.04 | 22.63 | -8.58 | 6.19 | 0.56 | - | ||
| 2023/11 | 2.06 | 1.38 | 26.12 | 20.54 | -11.11 | 6.13 | 0.57 | - | ||
| 2023/10 | 2.04 | 0.38 | 26.44 | 18.48 | -13.95 | 5.99 | 0.58 | - | ||
| 2023/9 | 2.03 | 5.35 | 33.05 | 16.44 | -17.22 | 5.9 | 0.3 | - | ||
| 2023/8 | 1.92 | -1.3 | 26.55 | 14.42 | -21.4 | 5.6 | 0.32 | - | ||
| 2023/7 | 1.95 | 13.29 | 27.21 | 12.49 | -25.74 | 5.43 | 0.33 | - | ||
| 2023/6 | 1.72 | -2.1 | -4.88 | 10.54 | -31.05 | 5.11 | 0.37 | - | ||
| 2023/5 | 1.76 | 8.12 | -54.83 | 8.82 | -34.56 | 5.16 | 0.37 | 主要係子公司業績較去年同期減少，因去年同期正逢國內疫情延燒，子公司搶進快篩試劑通路，帶動去年當期業績大幅成長。 | ||
| 2023/4 | 1.63 | -8.67 | -11.63 | 7.06 | -26.33 | 5.13 | 0.37 | - | ||
| 2023/3 | 1.78 | 3.48 | -31.31 | 5.44 | -29.82 | 5.44 | 0.31 | - | ||
| 2023/2 | 1.72 | -11.09 | -28.36 | 3.66 | -29.06 | 5.3 | 0.31 | - | ||
| 2023/1 | 1.94 | 17.68 | -29.67 | 1.94 | -29.67 | 5.22 | 0.32 | - | ||
| 2022/12 | 1.64 | 0.53 | -33.23 | 24.76 | -16.84 | 4.89 | 0.72 | - | ||
| 2022/11 | 1.64 | 1.64 | -35.19 | 23.11 | -15.36 | 4.77 | 0.74 | - | ||
| 2022/10 | 1.61 | 5.62 | -38.32 | 21.48 | -13.34 | 4.65 | 0.76 | - | ||
| 2022/9 | 1.52 | 0.2 | -33.34 | 19.87 | -10.4 | 4.58 | 0.31 | - | ||
| 2022/8 | 1.52 | -0.79 | -43.54 | 18.34 | -7.76 | 4.86 | 0.29 | - | ||
| 2022/7 | 1.53 | -15.29 | -41.01 | 16.82 | -2.15 | 7.23 | 0.2 | - | ||
| 2022/6 | 1.81 | -53.51 | -23.01 | 15.29 | 4.75 | 7.54 | 0.29 | - | ||
| 2022/5 | 3.89 | 111.55 | 57.32 | 13.48 | 10.09 | 8.33 | 0.26 | 主要係子公司於今年國內疫情延燒期間積極搶進快篩試劑市場通路佈局，帶動流通事業的業績大幅成長。 | ||
| 2022/4 | 1.84 | -29.01 | -28.5 | 9.59 | -1.87 | 6.83 | 0.32 | - | ||
| 2022/3 | 2.59 | 7.93 | 4.5 | 7.75 | 7.65 | 7.75 | 0.56 | - | ||
| 2022/2 | 2.4 | -12.72 | 5.96 | 5.15 | 9.3 | 7.62 | 0.57 | - | ||
| 2022/1 | 2.75 | 11.72 | 12.4 | 2.75 | 12.4 | 7.74 | 0.56 | - | ||
| 2021/12 | 2.46 | -2.41 | 7.52 | 29.77 | -16.43 | 7.6 | 0.72 | - | ||
| 2021/11 | 2.52 | -3.25 | -19.27 | 27.31 | -18.08 | 7.42 | 0.74 | - | ||
| 2021/10 | 2.61 | 14.14 | -1.15 | 24.78 | -17.95 | 7.59 | 0.72 | - | ||
| 2021/9 | 2.29 | -15.12 | -32.73 | 22.17 | -19.56 | 7.58 | 0.61 | - | ||
| 2021/8 | 2.69 | 3.65 | -26.66 | 19.89 | -17.71 | 7.64 | 0.6 | - | ||
| 2021/7 | 2.6 | 10.56 | -27.02 | 17.19 | -16.11 | 7.42 | 0.62 | - | ||
| 2021/6 | 2.35 | -5.01 | -24.8 | 14.59 | -13.81 | 7.4 | 0.65 | - | ||
| 2021/5 | 2.47 | -3.86 | -12.0 | 12.24 | -11.33 | 7.53 | 0.64 | - | ||
| 2021/4 | 2.57 | 3.75 | -20.37 | 9.77 | -11.16 | 7.32 | 0.66 | - | ||
| 2021/3 | 2.48 | 9.43 | -16.07 | 7.2 | -7.32 | 7.2 | 0.58 | - | ||
| 2021/2 | 2.27 | -7.42 | 14.71 | 4.72 | -1.95 | 7.01 | 0.6 | - | ||
| 2021/1 | 2.45 | 6.87 | -13.57 | 2.45 | -13.57 | 7.87 | 0.53 | - | ||
| 2020/12 | 2.29 | -26.74 | -43.52 | 35.63 | -7.58 | 8.06 | 0.68 | - | ||
| 2020/11 | 3.13 | 18.46 | 1.0 | 33.33 | -3.35 | 9.17 | 0.6 | - | ||
| 2020/10 | 2.64 | -22.31 | -19.15 | 30.21 | -3.78 | 9.71 | 0.56 | - | ||
| 2020/9 | 3.4 | -7.46 | -4.79 | 27.57 | -2.0 | 10.63 | 0.32 | - | ||
| 2020/8 | 3.67 | 3.14 | 5.85 | 24.17 | -1.59 | 10.36 | 0.33 | - | ||
| 2020/7 | 3.56 | 13.91 | 4.59 | 20.5 | -2.82 | 9.5 | 0.36 | - | ||
| 2020/6 | 3.13 | 11.16 | 1.45 | 16.93 | -4.25 | 9.17 | 0.59 | - | ||
| 2020/5 | 2.81 | -13.0 | -11.76 | 13.81 | -5.45 | 9.0 | 0.6 | - | ||
| 2020/4 | 3.23 | 9.36 | 7.02 | 11.0 | -3.69 | 8.16 | 0.66 | - | ||
| 2020/3 | 2.96 | 49.57 | 5.26 | 7.76 | -7.54 | 7.76 | 0.73 | - | ||
| 2020/2 | 1.98 | -30.25 | -12.05 | 4.81 | -13.98 | 8.87 | 0.64 | - | ||
| 2020/1 | 2.83 | -30.16 | -15.27 | 2.83 | -15.27 | 0.0 | N/A | - | ||
| 2019/12 | 4.06 | 31.02 | 35.93 | 38.55 | 21.42 | 0.0 | N/A | - |
| 年/月 | 營收 | 年/月 | 營收 | 年/月 | 營收 | 年/月 | 營收 | 年/月 | 營收 |
|---|---|---|---|---|---|---|---|---|---|
| 2024/1 | 2.41 | 2023/1 | 1.94 | 2022/1 | 2.75 | 2021/1 | 2.45 | 2020/1 | 2.83 |
| 2024/2 | 2.14 | 2023/2 | 1.72 | 2022/2 | 2.4 | 2021/2 | 2.27 | 2020/2 | 1.98 |
| 2024/3 | 2.45 | 2023/3 | 1.78 | 2022/3 | 2.59 | 2021/3 | 2.48 | 2020/3 | 2.96 |
| 2024/4 | 2.27 | 2023/4 | 1.63 | 2022/4 | 1.84 | 2021/4 | 2.57 | 2020/4 | 3.23 |
| 2024/5 | 2.34 | 2023/5 | 1.76 | 2022/5 | 3.89 | 2021/5 | 2.47 | 2020/5 | 2.81 |
| 2024/6 | 2.33 | 2023/6 | 1.72 | 2022/6 | 1.81 | 2021/6 | 2.35 | 2020/6 | 3.13 |
| 2024/7 | 2.32 | 2023/7 | 1.95 | 2022/7 | 1.53 | 2021/7 | 2.6 | 2020/7 | 3.56 |
| 2024/8 | 2.48 | 2023/8 | 1.92 | 2022/8 | 1.52 | 2021/8 | 2.69 | 2020/8 | 3.67 |
| 2024/9 | 2.57 | 2023/9 | 2.03 | 2022/9 | 1.52 | 2021/9 | 2.29 | 2020/9 | 3.4 |
| 2024/10 | 2.65 | 2023/10 | 2.04 | 2022/10 | 1.61 | 2021/10 | 2.61 | 2020/10 | 2.64 |
| 2024/11 | 2.48 | 2023/11 | 2.06 | 2022/11 | 1.64 | 2021/11 | 2.52 | 2020/11 | 3.13 |
| N/A | N/A | 2023/12 | 2.09 | 2022/12 | 1.64 | 2021/12 | 2.46 | 2020/12 | 2.29 |
- 每季的合約負債通常會反應在未來半年到一年後的營收
| 合約負債 QoQ YoY | |||
|---|---|---|---|
